160 related articles for article (PubMed ID: 31725063)
21. Breakthrough Hypersensitivity Reactions to Gadolinium-based Contrast Agents and Strategies to Decrease Subsequent Reaction Rates: A Systematic Review and Meta-Analysis.
Walker DT; Davenport MS; McGrath TA; McInnes MDF; Shankar T; Schieda N
Radiology; 2020 Aug; 296(2):312-321. PubMed ID: 32427558
[TBL] [Abstract][Full Text] [Related]
22. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
[TBL] [Abstract][Full Text] [Related]
23. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
Runge VM
Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
[TBL] [Abstract][Full Text] [Related]
24. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists.
Costa AF; van der Pol CB; Maralani PJ; McInnes MDF; Shewchuk JR; Verma R; Hurrell C; Schieda N
Can Assoc Radiol J; 2018 Nov; 69(4):373-382. PubMed ID: 30249408
[TBL] [Abstract][Full Text] [Related]
25. Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study.
Tibussek D; Rademacher C; Caspers J; Turowski B; Schaper J; Antoch G; Klee D
Radiology; 2017 Oct; 285(1):223-230. PubMed ID: 28640695
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate.
Kobayashi M; Levendovszky SR; Hippe DS; Hasegawa M; Murata N; Murata K; Marshall DA; Gonzalez-Cuyar LF; Maravilla KR
Radiology; 2021 Sep; 300(3):559-569. PubMed ID: 34128720
[TBL] [Abstract][Full Text] [Related]
27. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
[TBL] [Abstract][Full Text] [Related]
28. Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.
Behzadi AH; Zhao Y; Farooq Z; Prince MR
Radiology; 2018 Feb; 286(2):471-482. PubMed ID: 28846495
[TBL] [Abstract][Full Text] [Related]
29. Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
Sardanelli F; Cozzi A; Trimboli RM; Schiaffino S
AJR Am J Roentgenol; 2020 Feb; 214(2):324-327. PubMed ID: 31799869
[No Abstract] [Full Text] [Related]
30. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.
McDonald RJ; McDonald JS; Kallmes DF; Jentoft ME; Murray DL; Thielen KR; Williamson EE; Eckel LJ
Radiology; 2015 Jun; 275(3):772-82. PubMed ID: 25742194
[TBL] [Abstract][Full Text] [Related]
31. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan).
Runge VM
Invest Radiol; 2018 Oct; 53(10):571-578. PubMed ID: 30130320
[TBL] [Abstract][Full Text] [Related]
32. Gadolinium Retention in the Central and Peripheral Nervous System: Implications for Pain, Cognition, and Neurogenesis.
Alkhunizi SM; Fakhoury M; Abou-Kheir W; Lawand N
Radiology; 2020 Nov; 297(2):407-416. PubMed ID: 32808889
[TBL] [Abstract][Full Text] [Related]
33. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus.
Runge VM
Invest Radiol; 2016 May; 51(5):273-9. PubMed ID: 26945278
[TBL] [Abstract][Full Text] [Related]
34. Speciation Analysis of Gadolinium in the Water-Insoluble Rat Brain Fraction After Administration of Gadolinium-Based Contrast Agents.
Strzeminska I; Factor C; Robert P; Szpunar J; Corot C; Lobinski R
Invest Radiol; 2021 Sep; 56(9):535-544. PubMed ID: 33813574
[TBL] [Abstract][Full Text] [Related]
35. Pediatric Brain: Gadolinium Deposition in Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images Is Dependent on the Type of Contrast Agent.
Ryu YJ; Choi YH; Cheon JE; Lee WJ; Park S; Park JE; Kim WS; Kim IO
Invest Radiol; 2018 Apr; 53(4):246-255. PubMed ID: 29300210
[TBL] [Abstract][Full Text] [Related]
36. Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents.
Richter H; Bücker P; Martin LF; Dunker C; Fingerhut S; Xia A; Karol A; Sperling M; Karst U; Radbruch A; Jeibmann A
Radiology; 2021 Dec; 301(3):637-642. PubMed ID: 34546128
[TBL] [Abstract][Full Text] [Related]
37. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
[TBL] [Abstract][Full Text] [Related]
38. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Layne KA; Dargan PI; Archer JRH; Wood DM
Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
[TBL] [Abstract][Full Text] [Related]
39. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America.
Mithal LB; Patel PS; Mithal D; Palac HL; Rozenfeld MN
Pediatr Radiol; 2017 May; 47(6):657-664. PubMed ID: 28283727
[TBL] [Abstract][Full Text] [Related]
40. Are some agents less likely to deposit gadolinium in the brain?
Radbruch A
Magn Reson Imaging; 2016 Dec; 34(10):1351-1354. PubMed ID: 27629022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
